JeanMarie Guenot was trained in physical and medicinal chemistry at the University of California, San Francisco where she earned her Ph.D. Her interests turned to business, receiving her MBA from The Wharton School located at the Univerity of Pennsylvania. These academic interests thrust JeanMarie Guenot into opposite directions, or so it seems.
She has worked in the pharmaceutical and biotechnology industry. Jeanmarie Guenot has focused her interests in molecular dynamics, protein structure prediction research and drug design. For instance, she used these scientific tools to discover new drugs to fight cancer. Her business interests propelled her into a world of scientific discovery and the marketplace.
Jeanmarie Guenot’s scientific and her eventual business goals were to develop targeted therapies to treat diseases. Her training in the study of the underlying molecular mechanisms of diseases was critical to develop targeted pharmacological agents.
Of all of her accomplishments, of which there are many, was her recognition of the importance in developing targeted pharmacological agents, is her greatest achievement on amphivena.com. This inciteful recognition was the first building block to cure such diseases as cancer, one infected cell at a time.
Her interests in the treatment of severe eye diseases such as glaucoma, macular degeneration, and ocular inflammation, inspired her to found and manage SKS Ocular. Hoffmann-La Roche hired her as its principal scientist for the development of drugs for autoimmune diseases, and drugs to treat cancerous tumors.
Guenot was appointed at PDL BioPharma as its Vice President of Corporate & Business Development where she was accomplished in licensing, mergers and acquisitions. She was instrumental in securing a $800 million dollar transaction which included a $100 million dollar equity investment in PDL
Currently, she is the President & CEO of Amphivena Therapeutics, Inc. which has developed targeted antibody therapies to treat hematologic malignancies. The Food and Drug Administration is allowing an Amphivena drug, AMV564, for its use in human clinical trials at https://www.linkedin.com/in/jeanmarie-guenot-4a140617.
One-on-one with JeanMarie Guenot is where she has the most to offer. There are many lessons that she could teach, which she shares with her followers on Facebook.